Cryosite (ASX:CTE)

Executive Summary

Cryosite Limited (ASX:CTE) is an Australian public company specializing in outsourced clinical trial logistics, biological storage, and cell & gene therapy depot services. Founded in 2000 and headquartered in South Granville, the company operates GMP-certified, temperature-controlled facilities ranging from ambient to liquid nitrogen storage. Its validated warehouse management system supports end-to-end supply chain solutions, including import, storage, distribution, reverse logistics, and compliance management for pharmaceutical, biotech, and CRO clients. With a workforce of 50–200 employees, Cryosite is positioned to capitalize on the growing demand for specialized cold chain logistics in the oncology, immunology, gene therapy, and cell therapy sectors. As a publicly traded entity on the ASX (ticker: CTE), the company has established a niche in the Australian market, though it faces competition from larger global logistics providers. Its focus on GMP compliance and depot services for advanced therapies differentiates it from general biostorage firms. While limited financial data is available, the company's commercial stage and ongoing operations suggest steady revenue from existing contracts, with potential for growth through expansion into new therapeutic areas or geographic regions. Key risks include dependency on a few large clients and the capital-intensive nature of facility upgrades.

Upcoming Catalysts (preview)

• 2026 H2Announcement of new contract win with a top 20 pharma company for cell therapy logistics40% success
• 2027 H1Expansion of liquid nitrogen storage capacity or new GMP-certified facility50% success
• 2027 H2Strategic partnership or acquisition to enter the Asian biostorage market30% success